News

AUM 302

Peer Review Publications:

Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer

Sean P. Kennedy, Michael O’Neill, Darren Cunningham, Oncogene(2020), 10 February 2020.

Poster Presentations:

"Co-targeting PIM kinase to overcome MET amplified resistance to EGFR TKIs in NSCLC"

2019 IASLC World Conference on Lung Cancer, Barcelona, September 7-10, 2019.

"Activation of the MACC1/PIM/cMyc axis confers resistance to PI3K/mTOR inhibition in PIK3CA mutant NSCLC"

2018 AACR Targeting PI3K/mTOR Signaling Conference, November 30-December 3, 2018, Boston MA.

"Evaluation of dual-acting PIM/PI3K inhibitor IBL-302 in preclinical breast cancer models"

2018 American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018 in Chicago.

"Elucidating the Role of PIM Kinase and Its Therapeutic Potential in NSCLC" and "Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC"

17th IASLC World Conference on Lung Cancer, Vienna, December 4-7, 2016.

"Targeting PIM kinase in NSCLC"

International Association of Lung Cancer (IASLC) 16th World Conference on Lung Cancer in Denver, CO September 6-9, 2015.

"Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/MTOR inhibitors in multiple myeloma"

20th Congress of the European Hematology Association (EHA) June 11 – 14, 2015, Vienna.

“Cotargeting of PIM, PI3K and Mtor in Mantle Cell Lymphoma (MCL)”

57th ASH Annual Meeting, Orlando, December 5-8, 2015.

“Combined inhibition of PIM and PI3 kinases shows an enhanced efficacy in a number of solid tumour cell lines”

American Association for Cancer Research (AACR) Annual Meeting 2014, April 5-9, San Diego, California.

FOLLOW US

  • Twitter
  • LinkedIn Social Icon

Copyright © 2012-2020 Inflection Biosciences, Inc. All Rights Reserved